These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34283904)

  • 1. Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight/obesity.
    Wang G; Wu P; Qiu Y; Dong X; Wang Y; Chi Y; Zhang F; Li Y; Zhang J; Huang Z; Du X; Du Z
    Arch Endocrinol Metab; 2021 Nov; 65(4):421-427. PubMed ID: 34283904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study.
    Zhang YL; Zhou C; Li XF; Yang MN; Tao L; Zheng XY; Jia YS
    Obes Sci Pract; 2019 Aug; 5(4):366-375. PubMed ID: 31452921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients.
    Gao L; Huang H; Zhang L; Zhang N; Fu Y; Zhu D; Bi Y; Feng W
    Exp Clin Endocrinol Diabetes; 2022 Jun; 130(6):358-367. PubMed ID: 34856624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study.
    Chen K; Chen L; Shan Z; Wang G; Qu S; Qin G; Yu X; Xin W; Hsieh TH; Mu Y
    Diabetes Obes Metab; 2024 Feb; 26(2):690-698. PubMed ID: 37945546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of nutrition intervention on the body composition and blood glucose in newly diagnosed patients with type 2 diabetes mellitus complicated with overweight and obesity].
    Lin B; Yang QB; Yu YC; Wang YF; Li SY; Jin C
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Dec; 52(12):1276-1280. PubMed ID: 30522230
    [No Abstract]   [Full Text] [Related]  

  • 6. Changes of serum omentin-1 levels in normal subjects, type 2 diabetes and type 2 diabetes with overweight and obesity in Chinese adults.
    Zhang Q; Zhu L; Zheng M; Fan C; Li Y; Zhang D; He Y; Yang H
    Ann Endocrinol (Paris); 2014 Jul; 75(3):171-5. PubMed ID: 24997770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss.
    Jacob S; Rabbia M; Meier MK; Hauptman J
    Diabetes Obes Metab; 2009 Apr; 11(4):361-71. PubMed ID: 19207292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.
    Eliasson B; Gudbjörnsdottir S; Cederholm J; Liang Y; Vercruysse F; Smith U
    Int J Obes (Lond); 2007 Jul; 31(7):1140-7. PubMed ID: 17264849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight/obesity patients with type 2 diabetes mellitus.
    Dai C; Zhu W
    Medicine (Baltimore); 2022 Oct; 101(43):e31334. PubMed ID: 36316938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model.
    Fang X; Du Z; Duan C; Zhan S; Wang T; Zhu M; Shi J; Meng J; Zhang X; Yang M; Zuo Y
    Life Sci; 2021 Apr; 270():118966. PubMed ID: 33482185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of Roux-en-Y gastrojejunostomy and LRYGB with small stomach pouch on type 2 diabetes mellitus in patients with BMI<35 kg/m(2).
    Yi B; Jiang J; Zhu L; Li P; Im I; Zhu S
    Surg Obes Relat Dis; 2015; 11(5):1061-8. PubMed ID: 25843397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients.
    Derosa G; Maffioli P; Ferrari I; Palumbo I; Randazzo S; D'Angelo A; Cicero AF
    J Clin Pharm Ther; 2011 Oct; 36(5):592-601. PubMed ID: 21070297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum adropin levels are decreased in Chinese type 2 diabetic patients and negatively correlated with body mass index.
    Zang H; Jiang F; Cheng X; Xu H; Hu X
    Endocr J; 2018 Jul; 65(7):685-691. PubMed ID: 29669965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal-weight visceral obesity promotes a higher 10-year atherosclerotic cardiovascular disease risk in patients with type 2 diabetes mellitus-a multicenter study in China.
    Zheng J; Hu Y; Xu H; Lei Y; Zhang J; Zheng Q; Li L; Tu W; Chen R; Guo Q; Zang X; You Q; Xu Z; Zhou Q; Wu X
    Cardiovasc Diabetol; 2023 Jun; 22(1):137. PubMed ID: 37308932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-naïve type 2 diabetic patients.
    Deng H; Lin S; Yang X; Lv J; Luo S; Zeng L; Weng J; Xu W;
    J Diabetes; 2019 Jul; 11(7):509-518. PubMed ID: 30520243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of laparoscopic sleeve gastrectomy on insulin secretion patterns in morbidly obese patients].
    Qian C; Zhu C; Gao J; Bu L; Zhou D; Li N; Qu S
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Jan; 21(1):61-67. PubMed ID: 29354901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated Serum TNF-
    Alzamil H
    J Obes; 2020; 2020():5076858. PubMed ID: 32089876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial.
    Shi L; Zhu J; Yang P; Tang X; Yu W; Pan C; Shen M; Zhu D; Cheng J; Ye X
    Obes Res Clin Pract; 2017; 11(5):607-615. PubMed ID: 28161303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TOTAL BODY ADIPOSITY, TRIGLYCERIDES, AND LEG FAT ARE INDEPENDENT RISK FACTORS FOR DIABETIC PERIPHERAL NEUROPATHY IN CHINESE PATIENTS WITH TYPE 2 DIABETES MELLITUS.
    Zhen Q; Yao N; Chen X; Zhang X; Wang Z; Ge Q
    Endocr Pract; 2019 Mar; 25(3):270-278. PubMed ID: 30913011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.